StemCells, Inc.
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
 | |
| Company type | Public |
|---|---|
| Industry | Biotechnology |
| Founded | 1 January 1992  |
| Headquarters | , United States |
Key people | Ian Massey (CEO) Irving L. Weissman, M.D. (Founder) |
| Website | www.stemcellsinc.com |
StemCells, Inc. is a public biopharmaceutical company headquartered in Newark, California, that is developing purified human neural stem cells (HuCNS-SCs) in the hopes of treating central nervous system disorders and paralysis. StemCells' HuCNS-SCs have the ability to differentiate into the three main types of cells found in the central nervous system: neurons, astrocytes and oligodendrocytes.[1][2]
They are being studied in early stage trials.[3][4]
On November 28, 2016, StemCells merged with Microbot Medical Ltd. and became Microbot Medical Inc.
References
- ^ Falco, Miriam. (Sept. 7, 2012). "A tiny step forward for spinal cord injuries."
- ^ Le Roux, Mariette. (March 5, 2014). "Science sees future beyond Paralympics."
- ^ http://www.clinicaltrials.gov/ct2/show/NCT02163876
- ^ "StemCells Inc says spinal injury therapy shows promise". Reuters. 2015-11-18. Retrieved 2015-12-23.